跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前精选AI 评分20

Sionna Therapeutics 提交 8-K,披露 2026 财年第三季度业绩公告

Sionna Therapeutics, Inc. (0002036042) (Filer)

AI 导读

Sionna Therapeutics 于 11 月 10 日提交 Form 8-K,称已发布截至 9 月 30 日季度的财务业绩和业务亮点公告。公告全文作为附件 99.1 提交;该信息为“提供”而非《证券交易法》第 18 条意义上的“申报”。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________

FORM 8-K

__________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 10, 2026

__________________________

SIONNA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

__________________________

Delaware001-4250484-2801521
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

SIONNA THERAPEUTICS, INC.

21 Hickory Drive, Suite 500

Waltham, MA02451

(Address of principal executive offices, including zip code)

617-819-2020

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.001 par value per shareSIONThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02    Results of Operations and Financial Condition.

On November 10, 2026, Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

99.1

Press Release of Sionna Therapeutics, Inc. dated November 10, 2026.

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sionna Therapeutics, Inc.

Date: November 10, 2026

By:/s/ Jennifer Fitzpatrick
Name:Jennifer Fitzpatrick
Title:Chief Legal Officer and Head of Program Management

来源:SEC EDGAR · 本站存档